オピオイド鎮痛薬の世界市場：製品タイプ別、用途別、投与経路別、流通チャネル別、地域別、機会、予測、2018年～2032年

世界のオピオイド鎮痛薬の市場規模は、2025年～2032年の予測期間中に4.10％のCAGRで拡大し、2024年の468億6,000万米ドルから2032年には644億8,000万米ドルに成長すると予測されています。オピオイド鎮痛薬の市場需要は、慢性疼痛問題の治療において非オピオイド薬や理学療法が有効でない場合の多剤併用による疼痛に対して、予測期間中に盛んになると予測されます。市場で入手可能な様々な治療オプションの迅速な作用発現と高い有効性が、オピオイド鎮痛薬の需要を高めています。

また、がん、関節炎、腰痛、心臓病などの慢性疼痛疾患の有病率の上昇が、市場におけるオピオイド鎮痛薬の需要増加につながっています。オピオイドの使用にまつわる安全性の懸念を解消し、乱用抑止効果のある製剤技術を駆使した新しい製剤の進歩が、市場の成長を後押ししています。過去数年にわたり、薬物の誤用は世界の健康上の大きな問題として浮上しています。疼痛緩和のためのオピオイド処方が大幅に増加し、その乱用率も高まっています。薬物中毒と処方オピオイドの過剰摂取の抑制は、乱用抑止剤を用いて効果的に管理することができます。FDAは、オピオイド乱用問題に対処するため、処方オピオイドの乱用抑止製剤（ADF）の開発を推進しています。政府は、乱用抑止型オピオイドは乱用されにくい医薬品への一歩ではありますが、乱用や中毒を防ぐものではないことを認めています。例えば、2024年2月、Hikma Pharmaceuticals PLCは、クエン酸フェンタニル注、USP 25mcg/0.5mLおよび50mcg/mLの発売を発表しました。要件にあるように、この注射剤は麻酔期間、前投薬、導入、術直後の維持に使用されます。また、全身麻酔や局所麻酔における麻薬性鎮痛の補助としても使用されます。

当レポートでは、世界のオピオイド鎮痛薬市場について調査し、市場の概要とともに、製品タイプ別、オピオイド鎮痛薬別、投与経路別、流通チャネル別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 米国の関税の影響

第5章 世界のオピオイド鎮痛薬市場の見通し、2018年～2032年

• 市場規模分析と予測
• 市場シェア分析と予測
  • 製品タイプ別
    • コデイン
    • モルヒネ
    • オキシコドン
    • ヒドロコドン
    • メサドン
    • メペリジン
    • フェンタニル
    • ヒドロモルフォン
    • オキシモルフォン
    • デキストロメトルファン
    • トラマドール
    • その他
  • オピオイド鎮痛薬別
    • 慢性疼痛
    • 急性疼痛
  • 投与経路別
    • 経口
    • 注射
    • その他
  • 流通チャネル別
    • 病院薬局
    • 小売薬局
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • 南米
    • 中東・アフリカ
  • 企業別市場シェア分析（上位5社およびその他- 金額別、2024年）
• 2024年の市場マップ分析

第6章 北米のオピオイド鎮痛薬市場の見通し、2018年～2032年

• 市場規模分析と予測
• 市場シェア分析と予測
• 国別市場評価
  • 米国
  • カナダ
  • メキシコ

第7章 欧州のオピオイド鎮痛薬市場の見通し、2018年～2032年

• ドイツ
• フランス
• イタリア
• 英国
• ロシア
• オランダ
• スペイン
• ポーランド

第8章 アジア太平洋のオピオイド鎮痛薬市場の見通し、2018年～2032年

• インド
• 中国
• 日本
• オーストラリア
• ベトナム
• 韓国
• インドネシア
• フィリピン

第9章 南米のオピオイド鎮痛薬市場の見通し、2018年～2032年

• ブラジル
• アルゼンチン

第10章 中東・アフリカのオピオイド鎮痛薬市場の見通し、2018年～2032年

• サウジアラビア
• アラブ首長国連邦
• 南アフリカ
• イスラエル

第11章 需要供給分析

第12章 輸出入の分析

第13章 バリューチェーン分析

第14章 ポーターのファイブフォース分析

第15章 PESTLE分析

第16章 価格分析

第17章 市場力学

• 市場の促進要因
• 市場の課題

第18章 市場動向と発展

第19章 規制枠組みとイノベーション

• 臨床試験
• 規制当局の承認

第20章 特許の情勢

第21章 ケーススタディ

第22章 競合情勢

• 市場リーダートップ5の競合マトリックス
• 参入企業トップ5のSWOT分析
• 市場の主要企業トップ10の情勢
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceuticals Industries Ltd.
  • Daiichi Sankyo Company, Limited
  • Hikma Pharmaceuticals
  • Purdue Pharma L.P.
  • Mundipharma Pty Limited
  • Endo International Plc
  • Protega Pharmaceuticals Inc.
  • Mallinckrodt Company

第23章 戦略的提言

第24章 調査会社について・免責事項

List of Tables

• Table 1: Pricing Analysis of Opioid Analgesics, 2024
• Table 2: Phase 1 Clinical Trials in Industry Globally
• Table 3: Phase 4 Clinical Trials in Industry Globally
• Table 4: Global Opioid Analgesics Market - Competition Matrix of Leading Companies, 2024

List of Figures

• Figure 1: Global Opioid Analgesics Market Size, By Value (USD Billion), 2018-2032F
• Figure 2: Global Opioid Analgesics Market Share, By Product Type, By Value, 2018-2032F
• Figure 3: Global Opioid Analgesics Market Share, By Application, By Value, 2018-2032F
• Figure 4: Global Opioid Analgesics Market Share, By Route of Administration, By Value, 2018-2032F
• Figure 5: Global Opioid Analgesics Market Share, By Distribution Channel, By Value, 2018-2032F
• Figure 6: Global Opioid Analgesics Market Share, By Region, By Value, 2018-2032F
• Figure 7: Global Opioid Analgesics Market Share, By Company, By Value, 2024
• Figure 8: Global Opioid Analgesics Market Map, By Product Type, By Value, 2024
• Figure 9: Global Opioid Analgesics Market Map, By Application, By Value, 2024
• Figure 10: Global Opioid Analgesics Market Map, By Route of Administration, By Value, 2024
• Figure 11: Global Opioid Analgesics Market Map, By Distribution Channel, By Value, 2024
• Figure 12: Global Opioid Analgesics Market Map, By Region, By Value, 2024
• Figure 13: North America Opioid Analgesics Market Size, By Value (USD Billion), 2018-2032F
• Figure 14: North America Opioid Analgesics Market Share, By Product Type, By Value, 2018-2032F
• Figure 15: North America Opioid Analgesics Market Share, By Application, By Value, 2018-2032F
• Figure 16: North America Opioid Analgesics Market Share, By Route of Administration, By Value, 2018-2032F
• Figure 17: North America Opioid Analgesics Market Share, By Distribution Channel, By Value, 2018-2032F
• Figure 18: North America Opioid Analgesics Market Share, By Country, By Value, 2018-2032F
• Figure 19: United States Opioid Analgesics Market Size, By Value (USD Billion), 2018-2032F
• Figure 20: United States Opioid Analgesics Market Share, By Product Type, By Value, 2018-2032F
• Figure 21: United States Opioid Analgesics Market Share, By Application, By Value, 2018-2032F
• Figure 22: United States Opioid Analgesics Market Share, By Route of Administration, By Value, 2018-2032F
• Figure 23: United States Opioid Analgesics Market Share, By Distribution Channel, By Value, 2018-2032F
• Figure 24: Canada Opioid Analgesics Market Size, By Value (USD Billion), 2018-2032F
• Figure 25: Canada Opioid Analgesics Market Share, By Product Type, By Value, 2018-2032F
• Figure 26: Canada Opioid Analgesics Market Share, By Application, By Value, 2018-2032F
• Figure 27: Canada Opioid Analgesics Market Share, By Route of Administration, By Value, 2018-2032F
• Figure 28: Canada Opioid Analgesics Market Share, By Distribution Channel, By Value, 2018-2032F
• Figure 29: Mexico Opioid Analgesics Market Size, By Value (USD Billion), 2018-2032F
• Figure 30: Mexico Opioid Analgesics Market Share, By Product Type, By Value, 2018-2032F
• Figure 31: Mexico Opioid Analgesics Market Share, By Application, By Value, 2018-2032F
• Figure 32: Mexico Opioid Analgesics Market Share, By Route of Administration, By Value, 2018-2032F
• Figure 33: Mexico Opioid Analgesics Market Share, By Distribution Channel, By Value, 2018-2032F
• Figure 34: Europe Opioid Analgesics Market Size, By Value (USD Billion), 2018-2032F
• Figure 35: Europe Opioid Analgesics Market Share, By Product Type, By Value, 2018-2032F
• Figure 36: Europe Opioid Analgesics Market Share, By Application, By Value, 2018-2032F
• Figure 37: Europe Opioid Analgesics Market Share, By Route of Administration, By Value, 2018-2032F
• Figure 38: Europe Opioid Analgesics Market Share, By Distribution Channel, By Value, 2018-2032F
• Figure 39: Europe Opioid Analgesics Market Share, By Country, By Value, 2018-2032F
• Figure 40: Germany Opioid Analgesics Market Size, By Value (USD Billion), 2018-2032F
• Figure 41: Germany Opioid Analgesics Market Share, By Product Type, By Value, 2018-2032F
• Figure 42: Germany Opioid Analgesics Market Share, By Application, By Value, 2018-2032F
• Figure 43: Germany Opioid Analgesics Market Share, By Route of Administration, By Value, 2018-2032F
• Figure 44: Germany Opioid Analgesics Market Share, By Distribution Channel, By Value, 2018-2032F
• Figure 45: United Kingdom Opioid Analgesics Market Size, By Value (USD Billion), 2018-2032F
• Figure 46: United Kingdom Opioid Analgesics Market Share, By Product Type, By Value, 2018-2032F
• Figure 47: United Kingdom Opioid Analgesics Market Share, By Application, By Value, 2018-2032F
• Figure 48: United Kingdom Opioid Analgesics Market Share, By Route of Administration, By Value, 2018-2032F
• Figure 49: United Kingdom Opioid Analgesics Market Share, By Distribution Channel, By Value, 2018-2032F
• Figure 50: France Opioid Analgesics Market Size, By Value (USD Billion), 2018-2032F
• Figure 51: France Opioid Analgesics Market Share, By Product Type, By Value, 2018-2032F
• Figure 52: France Opioid Analgesics Market Share, By Application, By Value, 2018-2032F
• Figure 53: France Opioid Analgesics Market Share, By Route of Administration, By Value, 2018-2032F
• Figure 54: France Opioid Analgesics Market Share, By Distribution Channel, By Value, 2018-2032F
• Figure 55: Spain Opioid Analgesics Market Size, By Value (USD Billion), 2018-2032F
• Figure 56: Spain Opioid Analgesics Market Share, By Product Type, By Value, 2018-2032F
• Figure 57: Spain Opioid Analgesics Market Share, By Application, By Value, 2018-2032F
• Figure 58: Spain Opioid Analgesics Market Share, By Route of Administration, By Value, 2018-2032F
• Figure 59: Spain Opioid Analgesics Market Share, By Distribution Channel, By Value, 2018-2032F
• Figure 60: Italy Opioid Analgesics Market Size, By Value (USD Billion), 2018-2032F
• Figure 61: Italy Opioid Analgesics Market Share, By Product Type, By Value, 2018-2032F
• Figure 62: Italy Opioid Analgesics Market Share, By Application, By Value, 2018-2032F
• Figure 63: Italy Opioid Analgesics Market Share, By Route of Administration, By Value, 2018-2032F
• Figure 64: Italy Opioid Analgesics Market Share, By Distribution Channel, By Value, 2018-2032F
• Figure 65: Russia Opioid Analgesics Market Size, By Value (USD Billion), 2018-2032F
• Figure 66: Russia Opioid Analgesics Market Share, By Product Type, By Value, 2018-2032F
• Figure 67: Russia Opioid Analgesics Market Share, By Application, By Value, 2018-2032F
• Figure 68: Russia Opioid Analgesics Market Share, By Route of Administration, By Value, 2018-2032F
• Figure 69: Russia Opioid Analgesics Market Share, By Distribution Channel, By Value, 2018-2032F
• Figure 70: Netherlands Opioid Analgesics Market Size, By Value (USD Billion), 2018-2032F
• Figure 71: Netherlands Opioid Analgesics Market Share, By Product Type, By Value, 2018-2032F
• Figure 72: Netherlands Opioid Analgesics Market Share, By Application, By Value, 2018-2032F
• Figure 73: Netherlands Opioid Analgesics Market Share, By Route of Administration, By Value, 2018-2032F
• Figure 74: Netherlands Opioid Analgesics Market Share, By Distribution Channel, By Value, 2018-2032F
• Figure 75: Poland Opioid Analgesics Market Size, By Value (USD Billion), 2018-2032F
• Figure 76: Poland Opioid Analgesics Market Share, By Product Type, By Value, 2018-2032F
• Figure 77: Poland Opioid Analgesics Market Share, By Application, By Value, 2018-2032F
• Figure 78: Poland Opioid Analgesics Market Share, By Route of Administration, By Value, 2018-2032F
• Figure 79: Poland Opioid Analgesics Market Share, By Distribution Channel, By Value, 2018-2032F
• Figure 80: Turkey Opioid Analgesics Market Size, By Value (USD Billion), 2018-2032F
• Figure 81: Turkey Opioid Analgesics Market Share, By Product Type, By Value, 2018-2032F
• Figure 82: Turkey Opioid Analgesics Market Share, By Application, By Value, 2018-2032F
• Figure 83: Turkey Opioid Analgesics Market Share, By Route of Administration, By Value, 2018-2032F
• Figure 84: Turkey Opioid Analgesics Market Share, By Distribution Channel, By Value, 2018-2032F
• Figure 85: Asia-Pacific Opioid Analgesics Market Size, By Value (USD Billion), 2018-2032F
• Figure 86: Asia-Pacific Opioid Analgesics Market Share, By Product Type, By Value, 2018-2032F
• Figure 87: Asia-Pacific Opioid Analgesics Market Share, By Application, By Value, 2018-2032F
• Figure 88: Asia-Pacific Opioid Analgesics Market Share, By Route of Administration, By Value, 2018-2032F
• Figure 89: Asia-Pacific Opioid Analgesics Market Share, By Distribution Channel, By Value, 2018-2032F
• Figure 90: Asia-Pacific Opioid Analgesics Market Share, By Country, By Value, 2018-2032F
• Figure 91: China Opioid Analgesics Market Size, By Value (USD Billion), 2018-2032F
• Figure 92: China Opioid Analgesics Market Share, By Product Type, By Value, 2018-2032F
• Figure 93: China Opioid Analgesics Market Share, By Application, By Value, 2018-2032F
• Figure 94: China Opioid Analgesics Market Share, By Route of Administration, By Value, 2018-2032F
• Figure 95: China Opioid Analgesics Market Share, By Distribution Channel, By Value, 2018-2032F
• Figure 96: India Opioid Analgesics Market Size, By Value (USD Billion), 2018-2032F
• Figure 97: India Opioid Analgesics Market Share, By Product Type, By Value, 2018-2032F
• Figure 98: India Opioid Analgesics Market Share, By Application, By Value, 2018-2032F
• Figure 99: India Opioid Analgesics Market Share, By Route of Administration, By Value, 2018-2032F
• Figure 100: India Opioid Analgesics Market Share, By Distribution Channel, By Value, 2018-2032F
• Figure 101: Japan Opioid Analgesics Market Size, By Value (USD Billion), 2018-2032F
• Figure 102: Japan Opioid Analgesics Market Share, By Product Type, By Value, 2018-2032F
• Figure 103: Japan Opioid Analgesics Market Share, By Application, By Value, 2018-2032F
• Figure 104: Japan Opioid Analgesics Market Share, By Route of Administration, By Value, 2018-2032F
• Figure 105: Japan Opioid Analgesics Market Share, By Distribution Channel, By Value, 2018-2032F
• Figure 106: Australia Opioid Analgesics Market Size, By Value (USD Billion), 2018-2032F
• Figure 107: Australia Opioid Analgesics Market Share, By Product Type, By Value, 2018-2032F
• Figure 108: Australia Opioid Analgesics Market Share, By Application, By Value, 2018-2032F
• Figure 109: Australia Opioid Analgesics Market Share, By Route of Administration, By Value, 2018-2032F
• Figure 110: Australia Opioid Analgesics Market Share, By Distribution Channel, By Value, 2018-2032F
• Figure 111: South Korea Opioid Analgesics Market Size, By Value (USD Billion), 2018-2032F
• Figure 112: South Korea Opioid Analgesics Market Share, By Product Type, By Value, 2018-2032F
• Figure 113: South Korea Opioid Analgesics Market Share, By Application, By Value, 2018-2032F
• Figure 114: South Korea Opioid Analgesics Market Share, By Route of Administration, By Value, 2018-2032F
• Figure 115: South Korea Opioid Analgesics Market Share, By Distribution Channel, By Value, 2018-2032F
• Figure 116: Vietnam Opioid Analgesics Market Size, By Value (USD Billion), 2018-2032F
• Figure 117: Vietnam Opioid Analgesics Market Share, By Product Type, By Value, 2018-2032F
• Figure 118: Vietnam Opioid Analgesics Market Share, By Application, By Value, 2018-2032F
• Figure 119: Vietnam Opioid Analgesics Market Share, By Route of Administration, By Value, 2018-2032F
• Figure 120: Vietnam Opioid Analgesics Market Share, By Distribution Channel, By Value, 2018-2032F
• Figure 121: Indonesia Opioid Analgesics Market Size, By Value (USD Billion), 2018-2032F
• Figure 122: Indonesia Opioid Analgesics Market Share, By Product Type, By Value, 2018-2032F
• Figure 123: Indonesia Opioid Analgesics Market Share, By Application, By Value, 2018-2032F
• Figure 124: Indonesia Opioid Analgesics Market Share, By Route of Administration, By Value, 2018-2032F
• Figure 125: Indonesia Opioid Analgesics Market Share, By Distribution Channel, By Value, 2018-2032F
• Figure 126: Philippines Opioid Analgesics Market Size, By Value (USD Billion), 2018-2032F
• Figure 127: Philippines Opioid Analgesics Market Share, By Product Type, By Value, 2018-2032F
• Figure 128: Philippines Opioid Analgesics Market Share, By Application, By Value, 2018-2032F
• Figure 129: Philippines Opioid Analgesics Market Share, By Route of Administration, By Value, 2018-2032F
• Figure 130: Philippines Opioid Analgesics Market Share, By Distribution Channel, By Value, 2018-2032F
• Figure 131: Middle East and Africa Opioid Analgesics Market Size, By Value (USD Billion), 2018-2032F
• Figure 132: Middle East and Africa Opioid Analgesics Market Share, By Product Type, By Value, 2018-2032F
• Figure 133: Middle East and Africa Opioid Analgesics Market Share, By Application, By Value, 2018-2032F
• Figure 134: Middle East and Africa Opioid Analgesics Market Share, By Route of Administration, By Value, 2018-2032F
• Figure 135: Middle East and Africa Opioid Analgesics Market Share, By Distribution Channel, By Value, 2018-2032F
• Figure 136: Middle East and Africa Opioid Analgesics Market Share, By Country, By Value, 2018-2032F
• Figure 137: South Africa Opioid Analgesics Market Size, By Value (USD Billion), 2018-2032F
• Figure 138: South Africa Opioid Analgesics Market Share, By Product Type, By Value, 2018-2032F
• Figure 139: South Africa Opioid Analgesics Market Share, By Application, By Value, 2018-2032F
• Figure 140: South Africa Opioid Analgesics Market Share, By Route of Administration, By Value, 2018-2032F
• Figure 141: South Africa Opioid Analgesics Market Share, By Distribution Channel, By Value, 2018-2032F
• Figure 142: Saudi Arabia Opioid Analgesics Market Size, By Value (USD Billion), 2018-2032F
• Figure 143: Saudi Arabia Opioid Analgesics Market Share, By Product Type, By Value, 2018-2032F
• Figure 144: Saudi Arabia Opioid Analgesics Market Share, By Application, By Value, 2018-2032F
• Figure 145: Saudi Arabia Opioid Analgesics Market Share, By Route of Administration, By Value, 2018-2032F
• Figure 146: Saudi Arabia Opioid Analgesics Market Share, By Distribution Channel, By Value, 2018-2032F
• Figure 147: UAE Opioid Analgesics Market Size, By Value (USD Billion), 2018-2032F
• Figure 148: UAE Opioid Analgesics Market Share, By Product Type, By Value, 2018-2032F
• Figure 149: UAE Opioid Analgesics Market Share, By Application, By Value, 2018-2032F
• Figure 150: UAE Opioid Analgesics Market Share, By Route of Administration, By Value, 2018-2032F
• Figure 151: UAE Opioid Analgesics Market Share, By Distribution Channel, By Value, 2018-2032F
• Figure 152: South America Opioid Analgesics Market Size, By Value (USD Billion), 2018-2032F
• Figure 153: South America Opioid Analgesics Market Share, By Product Type, By Value, 2018-2032F
• Figure 154: South America Opioid Analgesics Market Share, By Application, By Value, 2018-2032F
• Figure 155: South America Opioid Analgesics Market Share, By Route of Administration, By Value, 2018-2032F
• Figure 156: South America Opioid Analgesics Market Share, By Distribution Channel, By Value, 2018-2032F
• Figure 157: South America Opioid Analgesics Market Share, By Country, By Value, 2018-2032F
• Figure 158: Brazil Opioid Analgesics Market Size, By Value (USD Billion), 2018-2032F
• Figure 159: Brazil Opioid Analgesics Market Share, By Product Type, By Value, 2018-2032F
• Figure 160: Brazil Opioid Analgesics Market Share, By Application, By Value, 2018-2032F
• Figure 161: Brazil Opioid Analgesics Market Share, By Route of Administration, By Value, 2018-2032F
• Figure 162: Brazil Opioid Analgesics Market Share, By Distribution Channel, By Value, 2018-2032F
• Figure 163: Argentina Opioid Analgesics Market Size, By Value (USD Billion), 2018-2032F
• Figure 164: Argentina Opioid Analgesics Market Share, By Product Type, By Value, 2018-2032F
• Figure 165: Argentina Opioid Analgesics Market Share, By Application, By Value, 2018-2032F
• Figure 166: Argentina Opioid Analgesics Market Share, By Route of Administration, By Value, 2018-2032F
• Figure 167: Argentina Opioid Analgesics Market Share, By Distribution Channel, By Value, 2018-2032F
• Figure 168: Codeine Global Manufactured Quantity (In Tons), 2019-2023
• Figure 169: Codeine Consumption Distribution by Country, 2023
• Figure 170: Morphine Global Manufactured Quantity (In Tons), 2019-2023
• Figure 171: Morphine Consumption Distribution by Country, 2023
• Figure 172: Oxycodone Global Manufactured Quantity (In Tons), 2019-2023
• Figure 173: Oxycodone Consumption Distribution by Country, 2023
• Figure 174: Fentanyl Global Manufactured Quantity (In Tons), 2019-2023
• Figure 175: Fentanyl Consumption Distribution by Country, 2023
• Figure 176: Top 5 Applicants in Global Opioid Analgesics Market
• Figure 177: Top 5 Owners of Global Opioid Analgesics Market
• Figure 178: Total Patents Approved in Last 7 Years in the Global Opioid Analgesics Market

Global opioid analgesics market is projected to witness a CAGR of 4.10% during the forecast period 2025-2032, growing from USD 46.86 billion in 2024 to USD 64.48 billion in 2032. The market demand for opioid analgesic pharmaceutical products is anticipated to thrive in the forecast period for multimodal pain when non-opioid drugs or physical therapy is ineffective for treating chronic pain issues. The quick onset of action and high efficacy of various treatment options available in the market are increasing the demand for opioid analgesics.

Also, an increase in the prevalence of chronic pain conditions such as cancer, arthritis, and lower back pain, heart disease has led to an increase in demand for opioid analgesics in the market. Advancements in new formulations by resolving safety concerns around the use of opioids and abuse-deterrent formulation technology are boosting the growth of the market. Over the past few years, drug misuse has emerged as a major global health concern. The prescription of opioids for pain relief has increased substantially and so has the rate of abuse for them. Controlling drug addiction and prescription opioid overdoses can be effectively managed using abuse-deterrent formations. The FDA is pushing for the development of abuse-deterrent formulations (ADFs) for prescription opioids in an effort to address the opioid abuse problem. The government acknowledges that while abuse-deterrent opioids are a step toward potentially less abusive medicines, they are neither abuse nor addiction-proof. For instance, In February 2024, Hikma Pharmaceuticals PLC announced the launch of Fentanyl Citrate Injection, USP 25mcg/0.5mL and 50mcg/mL. As noted by requirements, it is used for anesthesia periods, premedication, induction, and maintenance in the immediate postoperative period. The injection is also used as an adjunct to narcotic analgesia in general or regional anesthesia.

Increasing Prevalence of Cancer to Boost the Market

Chronic pain is present in 20% to 50% of cancer patients. About 80% of advanced-stage cancer patients have moderate to severe pain. One meta-analysis of pooled data from 52 studies found that more than half of the participants reported pain. Cancer pain and pain flares are more likely to occur in younger patients than older patients. Advances in understanding the biological mechanisms of cancer-related pain have led to better-targeted and more effective use of opioids. The global burden of cancer has grown recently, so research into finding new therapies and improving patient outcomes has increased. The increase in the incidence of cancer directly relates to a greater need for pain management strategies that are efficacious. The major driver for the opioid analgesic market is increased research and development initiatives being taken for the treatment of cancer. It is a reality that an increase in knowledge of cancer-related pain is substantially increasing the use of opioid analgesics for pain management. This trend underlines the role of pain relief in cancer care, highlighting a need for providers to balance opioid use with strategies for minimizing misuse and dependence, thus leading to safer and more effective patient care. Researchers are increasingly focusing on developing new therapies and evaluating their efficacy and safety.

Increasing Prevalence of Chronic Pain

The growth of the opioid market is driven by the increasing prevalence of chronic pain, which is affecting millions of individuals globally with conditions such as chronic conditions, including arthritis, fibromyalgia, and neuropathic pain, are increasingly becoming common, and patients are seeking effective pain management solutions to enhance their quality of life. With the increasing prevalence of chronic pain, coupled with an aging population more likely to suffer from this condition, healthcare providers turn to opioids as the first line of treatment. Continued research and development for opioid formulations is also being undertaken to optimize their efficacy with minimal side effects, therefore fueling additional growth in the market. The ongoing development of opioid formulations continues toward improved efficacy but with reduced potential side effects and related dependency risks. These advances address the dual considerations of efficacy and safety in pain relief, patients and providers towards the management of chronic pain with opioids as part of treatment.

In August 2022, Adalvo Limited announced that the company had acquired its first branded product, Onsolis, after finalizing a deal with a leading US-based specialty pharmaceutical company. The brand is an opioid analgesic used in the management of persistent breakthrough pain in cancer patients who are already receiving and tolerant to opioid therapy for their underlying cancer pain. The ongoing development of opioid formulations continues toward improved efficacy but with reduced potential side effects and related dependency risks. These advances address the dual considerations of efficacy and safety in pain relief, nudging patients and providers toward the management of chronic pain with opioids as part of treatment.

Advancements in ADFs Support Market Expansion

To counter the use and abuse of opioids and to limit the utilization of opioids for legitimate purposes, various pharmaceutical companies are focusing on developing ADFs. These formulations are designed to make drug misuse cumbersome, and make it difficult for the consumer to crush, inject, or dissolve the drugs. ADF opioids have been introduced by various pharmaceutical companies, including Pfizer Inc. and Collegium Pharmaceutical, Inc., with regulatory approvals and physician preference. The marketing of safer opioids is critical for the continued market growth as it addresses concerns associated with opioid dependency. Different governments and regulatory bodies, in their attempts to promote the use of ADF opioids, are encouraging pharmaceutical companies to heavily invest in research and development activities to bring forth the next generation of formulations. The growing awareness of safer opioid alternatives among both patients and physicians is driving the demand for ADFs and providing lucrative growth opportunities for the market.

Codeine Segment to Dominate the Opioid Analgesics Market

The codeine market is likely to lead in the opioid analgesics market in view of its widespread use and application in clinical conditions for pain management. Codeine is a naturally occurring opioid and is most often preferred as an alternative due to its effective analgesic properties along with relatively lower severity of side effects compared with stronger opioids, making it a popular medicine for the treatment of mild to moderate pain, especially in outpatient settings. In addition, the availability of codeine in several formulations involving combination products with acetaminophen or aspirin makes it more attractive to prescribers and patients. The increasing prevalence of chronic pain disorders and the demand for better pain relief interventions will keep supporting this segment. Continued studies and development of codeine as the best therapeutic agent ensure that the opioid analgesics market will be dominated by codeine. There are several studies that are currently undergoing on Codeine, for instance, the National Superiority Clinical Trial to assess the combination of fixed dosage of Dipyrone and Codeine comparing the isolated use of components in the control of moderate to severe pain after open pelvic-abdominal surgery.

North America Dominates the Opioid Analgesics Market

North America dominates the opioid analgesics markets due to the high prevalence of chronic pain, neuropathic pain, and postoperative surgical pain. Chronic pain is a condition that affects the daily life of many adults in the United States. According to the Centers for Disease Control and Prevention (CDC), almost 21% of the U.S. population, i.e., 51.6 million adults' population, is affected by chronic pain, and 6.9% (17.1 million people) experienced severe chronic pain (i.e., chronic pain that causes significant limitation of daily activities), with a higher prevalence among non-Hispanic American Indians or Alaskans. According to CDC reports that analyzed data from the National Health Interview Survey, chronic pain lasts for at least three months and usually affects the ability to function and work. In contrast, high-impact chronic pain occurs when chronic pain significantly reduces the activities of daily living. Chronic pain is a major public health problem in the United States. The healthcare cost of chronic pain in America is estimated at USD 635 billion per year, according to a JAMA Network Open article.

Meanwhile, Asia-Pacific is expected to be the fastest growing region over the forecast period. The rising prevalence of chronic pain conditions, such as arthritis, cancer, and post-surgical pain, is a significant driver for the growth of Asia-Pacific opioid analgesics market. The demand for effective pain management solutions is increasing with an aging population across countries like China, Japan, and South Korea. The increasing number of cancer cases across the region is also driving the demand for opioid-based pain relief. In countries such as China, India, and Australia, cancer is one of the leading causes of mortality, and opioids are a crucial component of oncology care, particularly for managing end-of-life and palliative care pain.

China is anticipated to hold the major share in the Asia-Pacific opioid analgesics market owing to the country's aging population and increasing prevalence of chronic pain conditions are driving demand for effective pain management solutions. In 2024, approximately 3,246,625 new cancer cases and 1,699,066 cancer-related deaths occurred in China. Additionally, rising healthcare expenditure and improved access to medical services have expanded the availability of opioid analgesics. China's growing middle class and changing lifestyles also contribute to the increased use of these medications. Furthermore, advancements in pharmaceutical technology, including the development of abuse-deterrent formulations, have enhanced the safety and appeal of opioid analgesics. Overall, the combination of demographic trends, healthcare improvements, and innovation in drug formulations is fueling the expansion of the opioid analgesics market in China.

Future Market Scenario (2025-2032F)

In the opioid analgesic market over the past 10 years, considerable fluctuations have been observed mainly due to the increase in opioid crisis and regulatory control. Nevertheless, future scenarios will be formed through the development of healthcare practice, regulating the framework and achievements in pain management. Pharmaceutical companies are investing in developing abuse-deterrent formulations. These innovations can restore trust between doctors and patients and increase market acceptance. The opioid analgesics market is expected to remain stable, with growth potential in certain areas due to innovation and a growing understanding of pain management. Companies that focus on developing safer opioid formulations and alternative pain management solutions are likely to see growth, which is anticipated to drive the opioid analgesics market. Collaboration with regulators and healthcare providers is key to shaping a responsible future for the opioid analgesics market.

Impact of the U.S. Tariff on Global Opioid Analgesics Market

The imposition of the new tariffs on various pharmaceutical imports are expected to cause significant disruptions to the supply chains, influence pricing strategies, and propelling production costs. Additionally, the increased costs are expected to be passed on to the patients, resulting in high prices and reduced accessibility of the product. Meanwhile, disruptions in supply chains are expected to result in shortage of essential opioid analgesics, impacting the quality of care provided to the patient population.

In response to the tariffs, various pharmaceutical companies are focusing on reshoring their production to the United States, seeking exemption for critical medications, and diversifying their supply chains. Meanwhile, potential retaliatory tariffs from the affected regions could increase complications in the pharmaceutical landscape, affecting the availability of essential pharmaceutical products.

Key Players Landscape and Outlook

Significant market activities have been reported in recent times, including distribution agreements and acquisitions alongside several product launches. In May 2023 Trevena Inc., a biopharmaceutical company, announced that its partner, Jiangsu Nhwa Pharmaceutical Co., Ltd., a China-based pharmaceutical company, has received approval from China's National Medical Products Administration (NMPA) for Olinvyk (oliceridine). Olinvyk is an opioid agonist indicated to manage pain severe enough to require an intravenous opioid analgesic in adult patients whose alternative treatments are inadequate.

In April 2023, Rusan Pharma Ltd. submitted a proposal to the commission for approval to manufacture and market methadone oral solution 1 mg/ml, as well as an application for a BA/BE research and clinical trial exemption. Methadone oral solution 1 mg/ml is already approved product. But this firm is required to submit BA/BE study protocol for further review by the committee.

Pfizer invested USD 743 million in its manufacturing facility in Singapore, focusing on the production of critical Active Pharmaceutical Ingredients (APIs) used in antibiotics and oncology and pain management medications in July 2024. This investment aims to enhance Pfizer's capacity to manufacture APIs, ensuring a stable supply of essential ingredients for its drug portfolio. The Singapore site will play a crucial role in Pfizer's global supply chain, strengthening its ability to meet the growing demand for medicines.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Impact of the U.S. Tariffs

5. Global Opioid Analgesics Market Outlook, 2018-2032F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Products type
    • 5.2.1.1. Codeine
    • 5.2.1.2. Morphine
    • 5.2.1.3. Oxycodone
    • 5.2.1.4. Hydrocodone
    • 5.2.1.5. Methadone
    • 5.2.1.6. Meperidine
    • 5.2.1.7. Fentanyl
    • 5.2.1.8. Hydromorphone
    • 5.2.1.9. Oxymorphone
    • 5.2.1.10. Dextromethorphan
    • 5.2.1.11. Tramadol
    • 5.2.1.12. Others
  • 5.2.2. By Application
    • 5.2.2.1. Chronic Pain
    • 5.2.2.2. Acute Pain
  • 5.2.3. By Route of administration
    • 5.2.3.1. Oral
    • 5.2.3.2. Injectable
    • 5.2.3.3. Others
  • 5.2.4. By Distribution Channel
    • 5.2.4.1. Hospital Pharmacy
    • 5.2.4.2. Retail Pharmacy
    • 5.2.4.3. Others
  • 5.2.5. By Region
    • 5.2.5.1. North America
    • 5.2.5.2. Europe
    • 5.2.5.3. Asia-Pacific
    • 5.2.5.4. South America
    • 5.2.5.5. Middle East and Africa
  • 5.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 5.3. Market Map Analysis, 2024
  • 5.3.1. By Product Type
  • 5.3.2. By Application
  • 5.3.3. By Route of Administration
  • 5.3.4. By Distribution Channel
  • 5.3.5. By Region

6. North Opioid Analgesics Market Outlook, 2018-2032F*

• 6.1. Market Size Analysis & Forecast
  • 6.1.1. By Value
• 6.2. Market Share Analysis & Forecast
  • 6.2.1. By Products Type
    • 6.2.1.1. Codeine
    • 6.2.1.2. Morphine
    • 6.2.1.3. Oxycodone
    • 6.2.1.4. Hydrocodone
    • 6.2.1.5. Methadone
    • 6.2.1.6. Meperidine
    • 6.2.1.7. Fentanyl
    • 6.2.1.8. Hydromorphone
    • 6.2.1.9. Oxymorphone
    • 6.2.1.10. Dextromethorphan
    • 6.2.1.11. Tramadol
    • 6.2.1.12. Others
  • 6.2.2. By Application
    • 6.2.2.1. Chronic Pain
    • 6.2.2.2. Acute Pain
  • 6.2.3. By Route of Administration
    • 6.2.3.1. Oral
    • 6.2.3.2. Injectable
    • 6.2.3.3. Others
  • 6.2.4. By Distribution Channel
    • 6.2.4.1. Hospital Pharmacy
    • 6.2.4.2. Retail Pharmacy
    • 6.2.4.3. Others
  • 6.2.5. By Country Share
    • 6.2.5.1. United States
    • 6.2.5.2. Canada
    • 6.2.5.3. Mexico
• 6.3. Country Market Assessment
  • 6.3.1. United States Opioids Analgesics Market Outlook, 2018-2032F*
    • 6.3.1.1. Market Size Analysis & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share Analysis & Forecast
      • 6.3.1.2.1. By Product Type
        • 6.3.1.2.1.1. Codeine
        • 6.3.1.2.1.2. Morphine
        • 6.3.1.2.1.3. Oxycodone
        • 6.3.1.2.1.4. Hydrocodone
        • 6.3.1.2.1.5. Methadone
        • 6.3.1.2.1.6. Meperidine
        • 6.3.1.2.1.7. Fentanyl
        • 6.3.1.2.1.8. Hydromorphone
        • 6.3.1.2.1.9. Oxymorphone
        • 6.3.1.2.1.10. Dextromethorphan
        • 6.3.1.2.1.11. Tramadol
        • 6.3.1.2.1.12. Others
      • 6.3.1.2.2. By Application
        • 6.3.1.2.2.1. Chronic Pain
        • 6.3.1.2.2.2. Acute Pain
      • 6.3.1.2.3. By Route of Administration
        • 6.3.1.2.3.1. Oral
        • 6.3.1.2.3.2. Injectable
        • 6.3.1.2.3.3. Others
      • 6.3.1.2.4. By Distribution Channel
        • 6.3.1.2.4.1. Hospitals Pharmacy
        • 6.3.1.2.4.2. Retail Pharmacy
        • 6.3.1.2.4.3. Others
  • 6.3.2. Canada
  • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Opioid Analgesics Market Outlook, 2018-2032F

• 7.1. Germany
• 7.2. France
• 7.3. Italy
• 7.4. United Kingdom
• 7.5. Russia
• 7.6. Netherlands
• 7.7. Spain
• 7.8. Poland

8. Asia-Pacific Opioids Analgesics Market Outlook, 2018-2032F

• 8.1. India
• 8.2. China
• 8.3. Japan
• 8.4. Australia
• 8.5. Vietnam
• 8.6. South Korea
• 8.7. Indonesia
• 8.8. Philippines

9. South America Opioid Analgesics Market Outlook, 2018-2032F

• 9.1. Brazil
• 9.2. Argentina

10. Middle East and Africa Opioid Analgesics Market Outlook, 2018-2032F

• 10.1. Saudi Arabia
• 10.2. UAE
• 10.3. South Africa
• 10.4. Israel

11. Demand Supply Analysis

12. Import and Export Analysis

13. Value Chain Analysis

14. Porter's Five Forces Analysis

15. PESTLE Analysis

16. Pricing Analysis

17. Market Dynamics

• 17.1. Market Drivers
• 17.2. Market Challenges

18. Market Trends and Developments

19. Regulatory Framework and Innovation

• 19.1. Clinical Trials
• 19.2. Regulatory Approvals

20. Patent Landscape

21. Case Studies

22. Competitive Landscape

• 22.1. Competition Matrix of Top 5 Market Leaders
• 22.2. SWOT Analysis for Top 5 Players
• 22.3. Key Players Landscape for Top 10 Market Players
  • 22.3.1. Pfizer Inc.
    • 22.3.1.1. Company Details
    • 22.3.1.2. Key Management Personnel
    • 22.3.1.3. Products and Services
    • 22.3.1.4. Financials (As Reported)
    • 22.3.1.5. Key Market Focus and Geographical Presence
    • 22.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
  • 22.3.2. Sanofi S.A.
  • 22.3.3. Teva Pharmaceuticals Industries Ltd.
  • 22.3.4. Daiichi Sankyo Company, Limited
  • 22.3.5. Hikma Pharmaceuticals
  • 22.3.6. Purdue Pharma L.P.
  • 22.3.7. Mundipharma Pty Limited
  • 22.3.8. Endo International Plc
  • 22.3.9. Protega Pharmaceuticals Inc.
  • 22.3.10. Mallinckrodt Company

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

23. Strategic Recommendations

24. About Us and Disclaimer